Forty-one million Americans have no commercial insurance coverage for Wegovy right now. Not because the drug does not work. Not because the science is thin. Because their insurance covers the same molecule under a different brand name the moment a diabetes diagnosis hits the chart. Develop full-blown type 2 diabetes and suddenly you are covered. Try to prevent it? Pay $1,349 a month out of pocket.
That is the system. I am not editorializing. That is literally how it works.
I have been tracking the GLP-1 coverage situation for over a year, and the numbers keep getting worse. In 2026, the number of people with no commercial insurance coverage for Wegovy increased by 42% compared to 2025, leaving over 41 million people with no coverage. For those who do have coverage for GLP-1 agonists prescribed for weight loss, over 88% still have to meet additional requirements like prior authorization. Meanwhile, in 2025, nearly all health plans covered GLP-1s for diabetes, and 49 percent of plans from companies with 500 or more employees covered them for weight loss. Coverage for the disease: almost universal. Coverage for the condition that creates the disease: a coin flip, contingent on your employer size.
The ROI on fixing this is, frankly, insane. And the cost of not fixing it is already landing on everyone's premiums.
The Biology Does Not Care About Your Billing Code
A Milken Institute report shows the annual economic impact of obesity in the United States exceeds $1.4 trillion, including treatment costs and lost productivity. The CDC puts the direct medical bill at almost $173 billion a year. In 2021, people with large employer private insurance who had an obesity or overweight diagnosis had an average of $12,588 in total annual health costs, more than double the $4,699 for those without such a diagnosis. Insurers are already paying for the wreckage. They are just paying for it in cardiac events, kidney disease hospitalizations, and joint replacements instead of Wegovy prescriptions.
The clinical data on what these drugs actually do to downstream health has gotten dramatically stronger. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in patients with established heart disease, independent of how much weight they lost. Read that sentence again carefully: independent of weight loss. The drug is doing something systemic. Patients using liraglutide or semaglutide reduced alcohol consumption by nearly two-thirds, and an observational study of 6,000 adults found that GLP-1 receptor agonists halved the risk of obesity-related cancers compared with usual care. Sleep apnea. Liver disease. Kidney disease progression. The indication list keeps expanding and insurers keep tightening the gate.
Obesity is an independent disease worthy of pharmacological intervention, even when it affects nondiabetic people who may otherwise be characterized as metabolically healthy. Boston University published that in JAMA Network Open. The science is not ambiguous. The policy is just lagging by a decade, as policy always does.
Alex will want more longitudinal adherence data before calling this a solved problem, and I respect that. The real-world discontinuation rates are a legitimate concern: about 22% of semaglutide users and 16% of tirzepatide users stopped treatment within the first year. But the solution to discontinuation is not to deny access. It is to structure coverage with coaching requirements and monitoring, which some large employers are already doing well.
Who Actually Gets Covered Right Now
Coverage is not just sparse. It is structurally inequitable. Only one in five firms with 200 or more workers, including 43% of firms with 5,000 or more workers, cover GLP-1 drugs for weight loss in their largest health plan. If you work at a small employer or are self-employed, you are essentially locked out. Rates of obtaining a prescription for semaglutide varied widely based on an individual's insurance plan and type, as well as job industry, sex, and use of other medications. Your industry determines your metabolic health outcomes. That should bother everyone, regardless of where you land on the political spectrum.
The federal picture is even more tangled. On April 4, 2025, the Trump Administration chose not to make the Biden-era Medicare obesity coverage proposal final, leaving GLP-1s covered by Medicare only if the beneficiary is prescribed the drug for diabetes, cardiovascular disease, or some other eligible diagnosis. Then in November, the calculus shifted again: President Trump announced deals with Eli Lilly and Novo Nordisk that slash prices and bring coverage to eligible Medicare and Medicaid beneficiaries for just a $50 copay. The BALANCE Model will launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027. Progress. Genuinely. But it is still contingent on qualifying diagnoses and voluntary insurer participation, meaning the access gap remains wide for tens of millions of people.
These medications cost typically about $617 to $766 per month, according to the Employee Benefits Research Institute. That is not a copay. That is a car payment. The people who most need intervention, those with the highest BMIs and the worst downstream risk profiles, are often the least able to absorb that cost independently.
The Budget Objection Is Real, but the Math Is Wrong
The cost argument against coverage is not stupid. In total, 34% of non-elderly people with employer-sponsored health insurance, roughly 36.2 million people, have a BMI that would medically qualify them for a GLP-1 drug. If even a fraction of those people get covered, drug spend goes up sharply in the near term. I understand why CFOs and benefits directors flinch. North Carolina's State Health Plan spent $100 million on GLP-1s for weight loss in 2023 and faced a projected $1.5 billion loss by 2030 before ultimately pulling coverage. That headline travels fast.
But here is the accounting error: research from the USC Schaeffer Center suggests GLP-1s could save Medicare up to $245 billion over 10 years by reducing demand for other services. A UChicago analysis published in JAMA Health Forum projected that if Medicare expanded coverage, three million beneficiaries would likely start using the drugs over the next decade, with drug costs totaling nearly $66 billion but about $18 billion saved through reduced hospitalizations and chronic disease care. The net cost is real. I am not pretending it evaporates. But it is being compared against the wrong baseline. The baseline is not zero cost. The baseline is $173 billion in annual obesity-related healthcare spending that is already baked into the system, compounding every year.
The dilemma for insurers is clear: they cannot afford GLP-1 therapies, but they also cannot afford not to cover them. That line is from a health economics analysis and it captures the trap exactly. The system is optimized to pay for sick people, not to prevent the sickness. GLP-1 coverage for weight loss is a test of whether American insurance can think longer than one calendar year.
My position is not that every person who wants Wegovy should get it free with no guardrails. Structured coverage with behavioral support, monitoring requirements, and BMI thresholds is reasonable and probably improves outcomes anyway. A Danish cohort study found participants combining behavioral support with individualized semaglutide dosing lost 16.7% of baseline weight over 64 weeks, matching clinical trial outcomes despite using half the typical drug dose. Less drug. Better adherence. Lower cost. That is the protocol worth building around.
The current system pays for the heart attack. It denies the drug that prevents it. That is not cost management. That is cost displacement, and we are all on the hook for where those costs land.
